Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018203613) PEPTIDE FOR TOLL-LIKE RECEPTOR (TLR) INHIBITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/203613 International Application No.: PCT/KR2018/004803
Publication Date: 08.11.2018 International Filing Date: 25.04.2018
IPC:
C07K 14/00 (2006.01) ,A61K 38/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
Applicants:
주식회사 젠센 GENESEN CO., LTD. [KR/KR]; 서울시 강남구 테헤란로 524, 9층 3호 3-ho, 9th Floor, 524, Teheran-ro Gangnam-Gu Seoul 06181, KR
Inventors:
최상돈 CHOI, Sang Dun; KR
권혁권 KWON, Hyuk Kwon; KR
신현준 SHIN, Hyeon Jun; KR
계향애 GUI, Xiang Ai; KR
Agent:
제일특허법인(유) FIRSTLAW P.C.; KR
Priority Data:
10-2017-005684204.05.2017KR
10-2018-004671523.04.2018KR
Title (EN) PEPTIDE FOR TOLL-LIKE RECEPTOR (TLR) INHIBITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
(FR) PEPTIDE POUR L'INHIBITION DU RÉCEPTEUR DE TYPE TOLL (TLR) ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
(KO) 톨-유사 수용체(TLR) 억제를 위한 펩타이드 및 이를 포함하는 약학적 조성물
Abstract:
(EN) The present invention relates to a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways as well as Toll-like receptor 4 (TLR4) and TLR3, and a pharmaceutical composition for preventing or treating TLR pathway mediated diseases. The fusion peptide of the present invention has an excellent effect of inhibiting TLR4 and various TLR pathways and can be effectively used in preventing and treating various TLR pathway mediated diseases caused by the signaling pathways, such as autoimmune diseases, inflammatory diseases and degenerative neurological diseases, by inhibiting the TLR mediated immune responses.
(FR) La présente invention concerne un polypeptide de fusion qui inhibe les voies de signalisation TLR1/2, TLR2/6, TLR7, TLR8 et TLR9 ainsi que le récepteur 4 de type Toll (TLR4) et TLR3 et une composition pharmaceutique destinée à prévenir ou à traiter des maladies médiées par la voie TLR. Le peptide de fusion de la présente invention présente un excellent effet d'inhibition de TLR4 et de diverses voies TLR et peut être utilisé efficacement dans la prévention et le traitement de diverses maladies, médiées par la voie TLR, provoquées par les voies de signalisation, telles que des maladies auto-immunes, des maladies inflammatoires et des maladies neurologiques dégénératives, par inhibition des réponses immunitaires médiées par TLR.
(KO) 본 발명은 TLR4(Toll-like receptor 4, 톨-유사 수용체 4)와 TLR3를 비롯한 TLR1/2, TLR2/6, TLR7, TLR8 및 TLR9 신호전달 경로를 억제하는 융합 펩타이드 및 이를 포함하는 TLR 경로 매개성 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명의 융합 펩타이드는 TLR4 및 다양한 TLR 경로를 억제하는 효과가 우수하여, 상기 TLR 매개된 면역 반응을 저해함으로써 상기 신호전달 경로에 의해 발생하는 다양한 TLR 경로 매개성 질환, 예컨대 자가면역 질환, 염증성 질환 또는 퇴행성 신경질환을 예방 및 치료하는데 유용하게 활용할 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)